ereprof. dr. Herman Mielants
Show
Sort by
-
- Journal Article
- A1
- open access
CARD15 gene polymorphisms in patients with spondyloarthropathies identify a specific phenotype previously related to Crohn's disease
-
A randomised placebo controlled 12 week trial of budesonide and prednisolone in rheumatoid arthritis
-
The influence of peripheral arthritis on disease activity in ankylosing spondylitis patients as measured with the bath ankylosing spondylitis disease activity index
-
Radiological scoring methods in Ankylosing Spondylitis. Reliability and change over 1 and 2 years
-
Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifestations
-
- Journal Article
- A1
- open access
Radiological sacroiliitis, a hallmark of spondylitis, is linked with CARD15 gene polymorphisms in patients with Crohn's disease
-
Diagnostic performance and predictive value of serum markers for the diagnosis of rheumatoid arthritis
-
What is the most appropriate radiologic scoring method for ankylosing spondylitis?
-
Radiological sacroiliitis is linked with CARD15 gene polymorphisms in patients with Crohn's disease
-
Scoring of radiographic progression in randomised clinical trials in ankylosing spondylitis: a preference for paired reading order
-
Measurement of spinal mobility in ankylosing spondylitis: Comparison of occiput-to-wall and tragus-to-wall distance
-
Structure-modifying capacity of anti-tumour necrosis factor-alpha therapy in Ankylosing spondylitis
-
The effect of infliximab on skin lesions in a patient with scleroderma (CREST)
-
Infliximab in patients who have spondyloarthropathy: clinical efficacy, safety and biological immunomodulation
-
Systematic safety follow-up in a cohort of 107 patients with spondylarthropathy treated with Infliximab: a new perspective of the role of host defence in the pathogenesis of the disease?
-
Crohn's disease patients with CARD15 variants have higher risk of developing axial joint involvement
-
CARD15 mutations in patients with spondyloarthropathy are linked with disease progression and evolution to Crohn's disease
-
Costs of ankylosing spondylitis in three European countries: the patient's perspective
-
Infliximab in patients who have spondyloarthropathy: clinical efficacy, safety, and biological immunomodulation
-
Anti-Saccharomyces cerevisiae IgA antibodies are raised in ankylosing spondylitis and undifferentiated spondyloarthropathy
-
Association between ASCA-positivity and carrier of a CARD-15 mutation in patients with Crohn's disease
-
Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease?
-
Direct costs of ankylosing spondylitis and its determinants: an analysis among three European countries
-
Assessment of enthesitis in ankylosing spondylitis
-
The gut in ankylosing spondylitis and other spondyloarthropathies: Inflammation beneath the surface
-
Successful use of infliximab in a patient with treatment resistant spondyloarthropathy related uveitis
-
Repeated infusions of infliximab, a chimeric anti-TNFα monoclonal antibody, in patients with active spondyloarthropathy: one year follow up
-
Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor α (infliximab) versus placebo in active spondylarthropathy
-
Immune linkages between inflammatory bowel disease and spondyloarthropathies.
-
Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries.
-
Gut inflammation and spondyloarthropathies.
-
Increase in lymphoid follicles and leukocyte adhesion molecules emphasizes a role for the gut in spondyloarthropathy pathogenesis.
-
Reliability of self assessed joint counts in ankylosing spondylitis.
-
Ankylosing spondylitis and bowel disease.
-
Influence of the gut and cytokine patterns in spondyloarthropathy.
-
Anti-tumour necrosis factor a therapy for ankylosing spondylitis: international experience.
-
Immunomodulatory effects of anti-tumor necrosis factor α therapy on synovium in spondylarthropathy: histologic findings in eight patients from an open-label pilot study
-
Current use of biologicals for the treatment of spondyloarthropathies.
-
New treatment options in spondyloarthropathies : increasing evidence for significant efficacy of anti-tumor necrosis factor therapy.
-
The proportion of Th1 cells, which prevail in gut mucosa, is decreased in inflammatory bowel syndrome.
-
Effects of anti-tumor necrosis factor alpha on synovium in patients with spondylarthropathy: Comment on the article by Baeten et al - Reply.
-
Gut mucosal T cell lines from ankylosing spondylitis patients are enriched with alpha E beta 7 integrin.
-
Treatment of active spondyloarthropathy with infliximab, the chimeric monoclonal antibody to tumour necrosis factor alpha.
-
Impaired Th1 cytokine production in spondyloarthropathy is restored by anti-TNFα
-
Flow cytometric analysis of gut mucosal lymphocytes supports an impaired Th1 cytokine profile in spondyloarthropathy.
-
Interpretation of ileal biopsies: morphological features in normal and diseased mucosa.
-
Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor α (infliximab) in spondyloarthropathy: an open pilot study
-
Comparative study of the synovial histology in rheumatoid arthritis, spondyloarthropathy, and osteoarthritis: influence of disease duration and activity
-
The zygapophyseal joint determines morphology of the enthesophyte
-
Chemical agents and enzymes used for the extraction of gut lymphocytes influence flow cytometric detection of T cell surface markers.